Article Information
History
- February 8, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Ella Petter1,2,
- Orna Mor3,4,
- Neta Zuckerman3,
- Danit Oz-Levi1,
- Asaf Younger1,
- Dvir Aran5,6,7 and
- Yaniv Erlich1,8,9,+
- 1MyHeritage Lab, Petach Tikva, Israel
- 2University of California Los Angeles, Los Angeles, 90095, CA, USA
- 3Central Virology Laboratory and Sheba Medical Center, Ministry of Health, Tel-Hashomer, Israel
- 4School of Public Health, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
- 5Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel
- 6The Taub Faculty of Computer Science, Technion-Israel Institute of Technology, Haifa, Israel
- 7Lorry I. Lokey Interdisciplinary Center for Life Sciences & Engineering, Technion-Israel Institute of Technology, Haifa, Israel
- 8The Interdisciplinary Center, Herzelia, Israel
- 9Eleven Therapeutics, Tel-Aviv, Israel
- ↵+To whom correspondence should be addressed (yaniv{at}myheritage.com)
Posted February 08, 2021.
Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2
